Today: 24 June 2026
Browse Category

Pharmaceuticals 13 February 2026 - 25 February 2026

GSK shares nudge up on $950 mln 35Pharma deal as dealmaking picks up

GSK shares nudge up on $950 mln 35Pharma deal as dealmaking picks up

GSK agreed to buy Canada’s 35Pharma for $950 million in cash, adding experimental pulmonary hypertension drug HS235 to its pipeline. GSK shares rose 0.1% to 2,204 pence in early London trading. The deal is subject to regulatory approval in the U.S. and Canada. GSK also reported buying back 462,000 shares as part of its ongoing share repurchase program.
25 February 2026
·
Dianthus Therapeutics (DNTH) stock rises ahead of TD Cowen conference; what investors watch next

Dianthus Therapeutics (DNTH) stock rises ahead of TD Cowen conference; what investors watch next

Dianthus Therapeutics shares rose 6.3% to $52.68 Monday ahead of CEO Marino Garcia’s scheduled fireside chat at TD Cowen’s health care conference on March 3. Volume reached about 944,000 shares. Investors are watching for updates on the company’s autoimmune pipeline and trial timelines. The event will be webcast and include one-on-one investor meetings.
24 February 2026
··
Novo Nordisk stock slips again as CagriSema miss drives forecast cuts and puts next catalysts in focus

Novo Nordisk stock slips again as CagriSema miss drives forecast cuts and puts next catalysts in focus

Novo Nordisk shares fell 2.5% to 245.1 Danish crowns Tuesday after its CagriSema obesity drug failed to match Eli Lilly’s tirzepatide in a Phase 3 trial. Barclays cut its peak sales forecast for CagriSema to $2 billion from $12 billion. Novo also reported mid-stage China trial results for its “triple G” obesity drug UBT251, showing up to 19.7% weight loss after 24 weeks.
24 February 2026
··
Eli Lilly stock pops after Novo trial miss, new Zepbound pen gets FDA nod

Eli Lilly stock pops after Novo trial miss, new Zepbound pen gets FDA nod

Eli Lilly shares climbed nearly 5% late Monday after Novo Nordisk reported its obesity drug CagriSema underperformed Lilly’s Zepbound in a head-to-head trial. Novo’s U.S.-listed shares dropped over 16%. CagriSema showed 23% weight loss after 84 weeks, compared to 25.5% for Zepbound. The trial failed to prove CagriSema was not worse than tirzepatide on weight loss.
23 February 2026
····
Organon stock jumps in premarket after MIUDELLA licensing deal, with 10-K filing in focus

Organon stock jumps in premarket after MIUDELLA licensing deal, with 10-K filing in focus

Organon shares jumped 7.8% to $8.10 in premarket trading Monday after the company announced a global licensing deal for MIUDELLA, a hormone-free copper IUD from Sebela Pharmaceuticals. Organon agreed to pay $27.5 million upfront and up to $505 million in sales-based milestones, pending antitrust and FDA approvals. The company’s dividend record date is Monday, with payment set for March 12.
23 February 2026
··
Vanda Pharmaceuticals stock jumps premarket after FDA clears Bysanti — what to watch at the open

Vanda Pharmaceuticals stock jumps premarket after FDA clears Bysanti — what to watch at the open

Vanda Pharmaceuticals shares jumped 33% to $7.68 in premarket trading Monday after the FDA approved its new antipsychotic pill, Bysanti, late Friday. The drug, milsaperidone, is bioequivalent to Vanda’s existing Fanapt and will be available commercially in the third quarter of 2026. Traders are watching whether the rally holds at the open and how Bysanti will compete in a crowded market.
23 February 2026
··
Johnson & Johnson stock price: JNJ heads into Monday as Tremfya data lands and dividend date nears

Johnson & Johnson stock price: JNJ heads into Monday as Tremfya data lands and dividend date nears

Johnson & Johnson shares closed at $242.49 on Friday, down 1.8%. The company released new three-year Tremfya data in ulcerative colitis over the weekend. J&J stock goes ex-dividend Feb. 24, with a $1.30-per-share payout set for March 10. A potential $20 billion sale of its DePuy Synthes orthopedics unit remains under discussion.
22 February 2026
···
Johnson & Johnson stock price: JNJ heads into Monday with DePuy sale talk and Tremfya data

Johnson & Johnson stock price: JNJ heads into Monday with DePuy sale talk and Tremfya data

Johnson & Johnson shares fell 1.8% to $242.49 Friday after Reuters reported the company is preparing a potential $20 billion sale of its DePuy Synthes orthopedics unit. J&J released new long-term data for Tremfya in ulcerative colitis, showing 80.8% remission at week 140. The company did not comment on the reported DePuy sale. Investors await management updates in March and April.
21 February 2026
··
GSK share price slips as Arexvy RSV data lands and stock goes ex-dividend

GSK share price slips as Arexvy RSV data lands and stock goes ex-dividend

GSK shares fell 0.4% in early London trading Thursday after the company released new real-world data on its RSV vaccine Arexvy and the stock went ex-dividend. A U.S. study linked Arexvy to reduced RSV-related hospitalisations and lower rates of major cardiovascular events in adults over 60. GSK also bought back 420,000 shares on Feb. 17. Investors await further RSV data and updates on dividends.
19 February 2026
····
Why CSL’s share price is moving: Lilly clazakizumab deal, buyback pace and the next dividend date

Why CSL’s share price is moving: Lilly clazakizumab deal, buyback pace and the next dividend date

CSL shares closed up 0.95% at A$154.19 in Sydney, marking a second consecutive gain after announcing a US$100 million licensing deal with Eli Lilly for clazakizumab. ASX filings showed CSL continued its share buyback and a director increased holdings. The stock remains about 15% below early-February levels. CEO Paul McKenzie is set to retire, with Gordon Naylor named interim chief.
19 February 2026
···
Why GSK stock is moving today: Exdensur EU nod and a fresh buyback

Why GSK stock is moving today: Exdensur EU nod and a fresh buyback

GSK shares rose 1.1% to 2,263 pence after the European Commission approved its twice-yearly asthma drug Exdensur and the company launched a new tranche of share buybacks. GSK will repurchase up to £0.45 billion in shares by April 24. The company also reported new real-world data showing its RSV vaccine Arexvy was 75.6% effective against RSV-related hospitalisation in adults over 60.
18 February 2026
··
Eli Lilly stock in focus as Retevmo lung cancer trial meets endpoint, with trading back Tuesday

Eli Lilly stock in focus as Retevmo lung cancer trial meets endpoint, with trading back Tuesday

Eli Lilly reported its cancer drug Retevmo beat placebo on event-free survival in a Phase 3 trial for early-stage RET fusion-positive non-small cell lung cancer. U.S. markets are closed for Presidents Day, delaying any stock reaction until Tuesday. Lilly shares last closed at $1,040, up 0.2% Friday. Full trial data will be presented at a future medical meeting.
16 February 2026
··
AbbVie stock ends higher Friday; what traders watch for ABBV after the Presidents Day break

AbbVie stock ends higher Friday; what traders watch for ABBV after the Presidents Day break

AbbVie shares closed up 1.8% at $231.50 Friday, outpacing Johnson & Johnson. U.S. markets will be closed Monday for Presidents Day, with trading set to resume Tuesday. Investors are weighing AbbVie’s drug-pricing moves and pipeline as the company shifts away from Humira after patent loss. Trading volume topped its recent average, with the stock about 5% below its 52-week high.
15 February 2026
··
Healthcare stocks head into Presidents Day break after Dexcom, Moderna lift XLV

Healthcare stocks head into Presidents Day break after Dexcom, Moderna lift XLV

The Health Care Select Sector SPDR Fund (XLV) rose 1.1% to $157.67 Friday, led by Dexcom’s 7.6% jump and Moderna’s 5.3% gain after earnings. Dexcom beat Q4 estimates and reiterated its 2026 outlook, while Moderna forecast up to 10% revenue growth, citing overseas markets. Broader markets saw tech lag as inflation data cooled. U.S. exchanges close Monday for Presidents Day.
15 February 2026
··
Vertex stock jumps nearly 6% on Oppenheimer upgrade as traders size up new drug pipeline

Vertex stock jumps nearly 6% on Oppenheimer upgrade as traders size up new drug pipeline

Vertex shares jumped 5.7% to $491.47 Friday after Oppenheimer upgraded the stock, citing growth plans beyond cystic fibrosis. The company set 2026 revenue guidance at up to $13.1 billion, with at least $500 million expected from new products. Vertex highlighted gene-editing, pain, and kidney therapies in its outlook. U.S. markets close Monday for Presidents Day.
14 February 2026
··
Moderna stock price jumps late after earnings beat, but FDA flu setback hangs over MRNA

Moderna stock price jumps late after earnings beat, but FDA flu setback hangs over MRNA

Moderna shares climbed 5% to $42.23 in after-hours trading Friday after beating fourth-quarter revenue estimates and reaffirming its 2026 growth outlook. The FDA refused to file Moderna’s flu vaccine application, prompting the company to seek a Type A meeting. The flu shot is under review in Europe, Canada, and Australia. Moderna reported Q4 revenue of $678 million and a $2.11 per share loss.
13 February 2026
····
1 … 4 5 6 7 8 … 42

Stock Market Updates

Nasdaq Futures Drop Ahead of Open as Debt Concerns Hit AI Stocks

Nasdaq edges lower in after-hours as AI chip fall spurs margin chatter

24 June 2026
Philadelphia SE Semiconductor index plunges 7.9%—over five times the S&P 500’s drop—as investors dump chip and AI stocks on fears of unsustainable capital spending; Cerebras Systems sinks 10% after hours on margin warning, while FedEx falls 6% post-close as core margins slip despite higher profit and revenue.
KB Home (NYSE:KBH) rises after hours as traders look to H2 delivery gains

KB Home (NYSE:KBH) rises after hours as traders look to H2 delivery gains

24 June 2026
KB Home jumped 4% after hours as investors bet on a back-loaded 2026 delivery plan, despite missing profit estimates; the builder must deliver 26% more homes in the second half to hit its target, with margins expected to edge up, while shares still trade below book value and buybacks continue.
Delta eyes higher margins as jet fuel drops; fares may follow

Delta eyes higher margins as jet fuel drops; fares may follow

24 June 2026
Delta CEO warns lower jet fuel prices alone won’t cut fares unless airlines can add more flights, as U.S. carriers paid $6.47 billion for fuel in April—up 78% from last year—while capacity growth is just 0.4% for Q3; Delta shares last traded at $86.72, up 81 cents.
IREN stock falls as Wall Street stays split on AI cloud payoff

IREN stock falls as Wall Street stays split on AI cloud payoff

24 June 2026
IREN plunged 3.78% to $54.72 as tech stocks tumbled on AI spending worries, but analysts remain split with targets from $36 to $100; Microsoft’s $9.7B contract and a new $3.65B GPU financing facility drive bullish bets, while risks from uncontracted revenue targets and delivery timelines leave the stock highly volatile.
Go toTop